Contact

financiación biotecnología

financiación biotecnología

We are together in each step
Array ( [0] => WP_Term Object ( [term_id] => 588 [name] => compra empresa biotecnologica [slug] => compra-empresa-biotecnologica [term_group] => 0 [term_taxonomy_id] => 588 [taxonomy] => post_tag [description] => [parent] => 0 [count] => 1 [filter] => raw ) [1] => WP_Term Object ( [term_id] => 260 [name] => financiación biotecnología [slug] => financiacion-biotecnologia [term_group] => 0 [term_taxonomy_id] => 260 [taxonomy] => post_tag [description] => [parent] => 0 [count] => 5 [filter] => raw ) [2] => WP_Term Object ( [term_id] => 589 [name] => grifols [slug] => grifols [term_group] => 0 [term_taxonomy_id] => 589 [taxonomy] => post_tag [description] => [parent] => 0 [count] => 2 [filter] => raw ) [3] => WP_Term Object ( [term_id] => 249 [name] => inversión en biotecnología [slug] => inversion-en-biotecnologia [term_group] => 0 [term_taxonomy_id] => 249 [taxonomy] => post_tag [description] => [parent] => 0 [count] => 4 [filter] => raw ) [4] => WP_Term Object ( [term_id] => 590 [name] => novartis [slug] => novartis [term_group] => 0 [term_taxonomy_id] => 590 [taxonomy] => post_tag [description] => [parent] => 0 [count] => 1 [filter] => raw ) )
La biotecnológica española consigue el apoyo de inversores internacionales
Según la OCDE España se sitúa en el top 10 de los países con mayor desarrollo del sector biotecnológico. Aunque est [...]
read more >>
Oryzon genomics floats on the MAB
Oryzon Genomics is listed on the MAB, reinforcing the biotech market, which is the largest listed on the MAB. From [...]
read more >>
France's Synerlab buys Alcalá Pharma
If a week ago we told you that Spanish biotechs were coming out on the MAB, this week it is the turn of Spanish biotechs [...].
read more >>
October 2015: Funding for the biotech sector: InnoUp Farma and Oryzon Genomics and Mind The Byte
In the second half of October we have witnessed that two Spanish companies focused on providing solutions for the [...]
read more >>
Minoryx y Sanifit reciben inversión de Caixa Capital Risk para luchar contra enfermedades raras.
El sector biotecnológico en general y el de las enfermedades raras en particular ha recibido el interés de Caixa Capit [...]
read more >>
closechevron-downcrossmenuchevron-down